Loading…
Biopol Chemicals (BIOPOL)₹45.90+0.99%Specialty Chemicals
In the Mar 2026 quarter (standalone), Biopol Chemicals reported sales of ₹49.52 Cr, up 46.1% from Mar 2025, and net profit of ₹6.05 Cr, up 101.0% year on year. For the year to Mar 2026, sales were ₹81.19 Cr and net profit ₹8.98 Cr.
Company filings, standalone accounts; latest reported quarter Mar 2026
| Mar 2025 | Sep 2025 | Mar 2026 | |
|---|---|---|---|
| Sales | 33.89 | 31.70 | 49.52 |
| Expenses | 29.32 | 27.21 | 40.37 |
| Operating Profit | 4.47 | 4.43 | 9.05 |
| OPM % | 13.2% | 14.0% | 18.3% |
| Other Income | 0.00 | 0.11 | 0.14 |
| Interest | 0.37 | 0.52 | 0.98 |
| Depreciation | 0.05 | 0.05 | 0.07 |
| Profit before tax | 4.05 | 3.95 | 8.12 |
| Tax % | 25.7% | 25.6% | 25.5% |
| Net Profit | 3.01 | 2.94 | 6.05 |
| EPS (Rs) | 3.78 | 3.69 | 5.57 |
| Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| Sales | 25.45 | 49.19 | 81.19 |
| Expenses | 20.96 | 42.48 | 67.54 |
| Operating Profit | 4.45 | 6.56 | 13.48 |
| OPM % | 17.5% | 13.4% | 16.6% |
| Other Income | 0.00 | 0.03 | 0.24 |
| Interest | 0.38 | 0.67 | 1.51 |
| Depreciation | 0.09 | 0.08 | 0.11 |
| Profit before tax | 3.97 | 5.83 | 12.08 |
| Tax % | 25.2% | 25.1% | 25.6% |
| Net Profit | 2.97 | 4.35 | 8.98 |
| EPS (Rs) | 3.73 | 5.48 | 8.28 |
| Dividend payout % | 0.0% | 0.0% | 0.0% |
| Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| Equity Capital | 7.88 | 7.87 | 10.77 |
| Reserves | 1.28 | 5.60 | 38.98 |
| Borrowings | 3.58 | 7.65 | 8.46 |
| Other Liabilities | 4.75 | 10.22 | 11.33 |
| Total Liabilities | 17.49 | 31.34 | 69.54 |
| Fixed Assets | 0.20 | 0.22 | 14.19 |
| CWIP | 0.07 | 0.00 | 0.13 |
| Investments | 0.00 | 0.00 | 0.00 |
| Other Assets | 17.22 | 31.12 | 55.22 |
| Inventories | 6.14 | 11.85 | 19.66 |
| Trade receivables | 10.14 | 16.67 | 27.81 |
| Cash & equivalents | 0.07 | 1.14 | 0.51 |
| Total Assets | 17.49 | 31.34 | 69.54 |
| Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| Cash from operating activity | −6.43 | −2.33 | −12.78 |
| Cash from investing activity | −0.63 | −0.01 | −14.50 |
| Cash from financing activity | 7.13 | 3.42 | 26.64 |
| Net cash flow | 0.05 | 1.06 | −0.62 |
| Capex | 0.04 | 0.03 | 14.13 |
| Free cash flow | −6.54 | −2.37 | −27.03 |
| CFO / OP % | −141.0% | −28.0% | −93.0% |
| Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| Debtor days | 146 | 125 | 126 |
| Inventory days | 122 | 108 | 114 |
| Days payable | 79 | 79 | 38 |
| Cash conversion cycle | 188 | 152 | 200 |
| Working capital days | 127 | 95 | 179 |
| ROCE % | — | 38.3% | 34.2% |
For the Mar 2026 quarter, Biopol Chemicals reported sales of ₹49.52 Cr, up 46.1% year on year and net profit of ₹6.05 Cr, up 101.0% year on year. The operating margin was 18.3%.
Biopol Chemicals' sales for the year to Mar 2026 were ₹81.19 Cr.
Net profit for the year to Mar 2026 was ₹8.98 Cr. Earnings per share over the same trailing period were ₹8.28.
Biopol Chemicals reported borrowings of ₹8.46 Cr at Mar 2026, against cash and equivalents of ₹0.51 Cr.
Cash from operations was −₹12.78 Cr in the year to Mar 2026; after capital spending, free cash flow was −₹27.03 Cr.